Orthofix International

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Orthofix and SeaSpine post mixed Q4 results, eye synergies and growth

SeaSpine and Orthofix reported mixed Q4 performances but demonstrated overall revenue growth for the full year, with positive revenue guidance for 2023.
The merger synergies and product demand strengths are key highlights, while challenges in profitability and regulatory hurdles in Europe require attention.
Opportunities lie in integration efforts, cost efficiencies, and exploring new markets, indicating a strategic growth trajectory for the combined entity.
The upcoming Analyst Teach-In event and focus on operational planning underscore the commitment to transparency and strategic alignment post-merger.

Orthofix reports robust Q1 earnings, raises full-year revenue guidance

Orthofix International's Q1 2023 earnings call highlighted strong financial performance, strategic initiatives, and raised revenue guidance, underscoring growth prospects.
The company's focus on operational efficiency, product categories, and profitability signals a resilient business strategy amidst market challenges and competitive landscape.
With a robust financial foundation, Orthofix is well-positioned to navigate challenges, capitalize on growth opportunities, and drive sustainable value creation for shareholders.

Orthofix International reports robust Q2 earnings and growth outlook

Orthofix International delivered a strong Q2 performance, with notable revenue growth and positive outlook for 2023.
Efforts to integrate merged businesses are yielding results, with a focus on revenue enhancement and operational streamlining.
Challenges such as cash flow and supply chain disruptions are being addressed through strategic investments and operational improvements.
The company's focus on growth, efficiency, and strategic partnerships positions it well for future success and value creation.

Orthofix reports robust Q3 revenue growth, eyes profitability and stability

Orthofix International demonstrated strong revenue growth and market performance in Q3 2023, driven by successful product lines and strategic initiatives.
While facing challenges such as cash flow outflows and margin adjustments, the company remains focused on profitability and financial stability.
Opportunities lie in sustaining positive momentum, achieving cash flow positivity in 2024, and leveraging growth prospects through product innovation and market expansion.

Orthofix reports robust Q4 earnings, eyes growth in key segments

Orthofix International's Q4 2023 earnings call highlighted strong financial performance, strategic initiatives, and growth in key segments.
The company's focus on market share, distributor relationships, and portfolio enhancements positions it well for future success.
Despite challenges in a competitive landscape, Orthofix remains optimistic about growth opportunities and aims for continued innovation and collaboration.

Orthofix International reports robust Q1 earnings and raises 2024 guidance

Orthofix International (OFIX) delivered a strong Q1 2024 performance, focusing on growth, innovation, and operational efficiency. The company showcased revenue growth, margin expansion, and strategic priorities for the year. Challenges include sustaining growth in competitive markets and optimizing operational aspects, while opportunities lie in leveraging technology and talent for further growth.

Orthofix International reports strong Q2 performance and outlines growth strategies

Orthofix International's Q2 performance reflects solid revenue growth and margin expansion, supported by new product releases and operational efficiency.
While facing challenges in cash flow optimization, the company's strategic focus on innovation and synergies positions it well for future growth.
Opportunities in technology investment, cross-selling, and distribution enhancements offer avenues for Orthofix International to drive sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LEWISVILLE, Texas--(BUSINESS WIRE)--The Rodeo nail is designed to address the biomechanical and procedural challenges associated with implanting in the fragile bone associated with OI.

Orthofix Announces FDA 510(k) Clearance for the Rodeo Telescopic Nail

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the first quarter ended March 31, 2024. First quarter net sales were $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis. Net loss was $(36.0) million and earnings per share ("EPS") was $(0.95) on a reported basis, representing an improvement of 44% when compared to the prior year period. Non-GAAP adjusted EBITDA was $7.7 million for the firs.

Orthofix Reports First Quarter 2024 Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its first quarter 2024 financial results on Tuesday, May 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 a.m. ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the even.

Orthofix Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024

NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Lost Money on Orthofix Medical Inc. (OFIX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Orthofix Medical Inc. (OFIX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Andres Cedron has joined the company as Chief Legal Officer. Cedron most recently served as Vice President and Corporate Secretary at Stryker Corporation, a $20B+ global medical device company. In his corporate officer position, Cedron oversaw Stryker's corporate governance, SEC compliance, mergers and acquisitions, and ESG matters. “With a broad breadth.

Orthofix Names Andres Cedron as New Chief Legal Officer

NEW YORK, NY / ACCESSWIRE / April 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

ATTENTION Orthofix Medical Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Levi & Korsinsky Reminds Orthofix Investors of the Ongoing Investigation into Potential Violations of Securities Laws - OFIX

NEW YORK, NY / ACCESSWIRE / April 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Orthofix Medical Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- OFIX

NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Shareholders that lost money on Orthofix Medical Inc.(OFIX) should contact Levi & Korsinsky about Securities Fraud Investigation - OFIX

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Shareholders that lost money on Orthofix Medical Inc. (OFIX) should contact Levi & Korsinsky about Securities Fraud Investigation - OFIX

NEW YORK, NY / ACCESSWIRE / March 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Lost Money on Orthofix Medical Inc.(OFIX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

ATTENTION OFIX SHAREHOLDERS: Investors who lost money on Orthofix Medical Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

OFIX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Orthofix Medical Inc. investment

NEW YORK, NY / ACCESSWIRE / March 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Levi & Korsinsky Reminds Shareholders of an Investigation into Orthofix Medical Inc. (OFIX) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

OFIX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Orthofix Medical Inc. Investment

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

OFIX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Orthofix Medical Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

An Investigation Has Commenced on Behalf of Orthofix Medical Inc. Shareholders. Contact Levi & Korsinsky to Discuss your OFIX Losses.

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Orthofix Medical Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - OFIX

Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Shareholder Rights Advocates at Levi & Korsinsky Investigate Orthofix Medical Inc. (OFIX) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

Orthofix Medical Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - OFIX

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Orthofix Medical Inc. ("Orthofix ") (NASDAQ:OFIX) concerning possible violations of federal securities laws. On September 12, 2023, Orthofix announced the "the unanimous decision by the Board's independent directors to terminate for cause" Orthofix's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer due to alleged violations of the Company's Code of Conduct.

OFIX ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Orthofix Medical Inc.

Orthofix Medical Inc. (NASDAQ:OFIX ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President of Gilmartin Group Massimo Calafiore - President and Chief Executive Officer Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Ryan Zimmerman - BTIG Destiny Hance - Ladenburg Thalmann Jason Wittes - Roth MKM Operator Good afternoon, and welcome to Orthofix Medical's Q4 and Full Year 2023 Earnings Call. All participants are in a listen-only mode.

Orthofix Medical Inc. (OFIX) Q4 2023 Earnings Call Transcript

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and year ended December 31, 2023, and issued guidance for the full year 2024. Fourth quarter net sales were $200.4 million, an increase of 64% on a reported basis and 7% on a pro forma constant currency basis. Net loss was $(22.2) million and earnings per share ("EPS") was $(0.59) on a reported basis, representing an improvement of 19% when compared to pro forma re.

News for Orthofix International Stock (OFIX)